Screening for Celiac Disease Using Anti Tissue Transglutaminase in Patients with Esophageal SCC between 2004 and 2009

Authors

  • Elham Mokhtari Amirmajdi Gastroenterologist, Gastroenterology and Hepatology, Nayshabour Faculty of Medical Sciences, Nayshabour, Iran
  • Hasan Vosoughinia Gastroenterologist, Department of Gastroenterology and Hepatology, Mashhad University of Medical Sciences, Mashhad, Iran
  • Mohammadtaghi shakeri Community Medicine Specialist, Department of Epidemiology & Social Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Ramin Sharifan Internal Medicine Specialist, Department of Internal Medicine, Azad University of Medical Sciences, Mashhad, Iran
  • Seyed Amir AleDavood Oncologist, Department of Radiotherapy and Oncology, Mashhad University of Medical Sciences, Mashhad, Iran
  • Siavosh Abedini Student of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract:

  Introduction: Esophageal Squamous-Cell Carcinoma (SCC) is one of the most common malignancies in Iran. To reduce the incidence of esophageal SCC, it is important to recognize the controllable risk factors and prevent them. Celiac disease is widely known as a possible risk factor for esophageal SCC.  Thus, we decided to assess the frequency of celiac disease in esophageal SCC patients in North east of Iran in order to suggest correlation between two diseases. Materials and Methods: In a Cross-sectional study one hundred and forty-three cases of esophageal SCC were examined for anti tissue transglutaminase antibody (anti-tTG) between the years 2004 and 2009 in Ghaem and Omid Hospitals of Mashhad University of Medical Sciences, Iran. The enzyme-linked immunosorbent assay was the test of choice in this study since it provides the sensitivity and specificity needed for the diagnosis and screening of celiac disease. The results of this test were compared with those of the control group which were compatible in terms of sex and age. Data were analyzed through SPSS software and statistical analysis such as x2, exact x2 and T-test. Results:19.6% patients (SCC) had positive anti-tTG (>20) which was significantly different to 7.9% in control group (p -value=0.005). Comparing age groups of patients for positive anti_tTG using exact x square test showed significant difference in patients with Conclusion: There seems to be a correlation between positive anti_tTG and esophageal SCC; that is to say, celiac disease might play a role in the earlier manifestations of esophageal SCC.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

screening for celiac disease using anti tissue transglutaminase in patients with esophageal scc between 2004 and 2009

introduction: esophageal squamous-cell carcinoma (scc) is one of the most common malignancies in iran. to reduce the incidence of esophageal scc, it is important to recognize the controllable risk factors and prevent them. celiac disease is widely known as a possible risk factor for esophageal scc.  thus, we decided to assess the frequency of celiac disease in esophageal scc patients in north e...

full text

Anti-Endomysial and Anti-Tissue Transglutaminase Serological Test Compared with Small Bowel Biopsy in the Diagnosis of Celiac Disease

Abstract Background and Objective: Celiac is an autoimmune disease that is characterized by an immune-system-related damage in the intestinal tissue after consumption of gluten. There is not any general agreement for gold standard. The Purpose of this study was the evaluation of specificity and sensitivity of anti-endomysial (EMA) and anti-tissue transglutaminase (TTG) serological test compa...

full text

The Diagnostic Value of Serum IgG-Antigliadin, IgA Anti-endomysial and IgA Anti-tissue Transglutaminase Antibodies for Pediatric Celiac Disease

  Background and Objective: Celiac disease is an autoimmune disorder, characterized by inflammation, villous atrophy, and crypt hyperplasia of the small bowel mucosa. In this study we considered and compared sensitivity and specificity of serological tests in patients with celiac disease. Materials and Methods: In this cross-sectional study we prospectively recruited children with suspected c...

full text

Intestinal Production of Anti-Tissue Transglutaminase 2 Antibodies in Patients with Diagnosis Other Than Celiac Disease

It has been hypothesized that gluten-dependent production of anti-tissue-transglutaminase 2 (anti-TG2) antibodies may occur only at an intestinal level. We have investigated intestinal production of anti-TG2 antibodies in 136 patients with normal serum levels of anti-TG2 antibodies and normal duodenal mucosa. Intestinal deposits of anti-TG2 antibodies were evaluated by immunofluorescence and an...

full text

Tissue transglutaminase enzyme-linked immunosorbent assay as a screening test for celiac disease in pediatric patients.

OBJECTIVE An immunoglobulin A (IgA) anti-tissue transglutaminase antibody assay (anti-tTG) was compared with the conventional IgA anti-endomysium antibody assay (EMA) to assess its reliability as a screening test for celiac disease (CD) in a pediatric population. METHODS Seventy-five IgA-sufficient and 2 IgA-deficient children who were scheduled for small intestinal biopsy for the evaluation ...

full text

Mucosal tissue transglutaminase expression in celiac disease

Tissue transglutaminase (tTG) plays an important role in celiac disease pathogenesis and antibodies to tTG are a diagnostic marker of gluten-sensitive enteropathy. The aim of this study was to investigate the localization of tTG in the duodenal mucosa in control tissues and in different histological stages of celiac disease by using a commercial and a novel set of anti-tTG monoclonal antibodies...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 3  issue 1

pages  254- 258

publication date 2015-01-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023